Initial Therapy: When Progression Occurs

Depending on dose, firmonertinib shrank tumors in 43% to 68% of patients as a first treatment for EGFR PACC-mutant lung cancer in the phase 1b FURTHER trial.

U.S. counties where more residents had medical debt in collections had higher rates of late-stage lung, head and neck, colorectal and several other cancers, according to a study of 2,958 counties published in October 2026 in JAMA Network Open.

Libtayo survival data, a rare positive osteosarcoma trial and new ADCs for breast, lung and stomach cancers are among ESMO 2026 abstracts to watch.

Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.

Learn why hepatitis B can reactivate during cancer treatment, which therapies increase the risk and how antiviral medicines can help protect liver health.

After her sister’s Hodgkin lymphoma diagnosis, remission and relapse, a caregiver reflects on follow-up care, guilt and finding hope between cancer battles.

After a pancreatic cancer diagnosis upended his life and career, one survivor reflects on treatment, resilience and finding hope more than a decade later.

The American Society of Hematology published 2026 guidelines for adults with myelofibrosis on Oct. 14, 2026, with 10 recommendations on genetic testing, JAK inhibitors, anemia, transplant referral and aspirin.